NTRA News and Press, Natera Inc. From 05/09/23

2023-05-09 23:07:08 ET Natera, Inc. (NTRA) Q1 2023 Earnings Conference Call May 09, 2023, 04:30 PM ET Company Participants Steven Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Alexey Aleshin - Chief Medical Officer John Fesko - Ch...

2023-05-09 16:25:19 ET Natera press release ( NASDAQ: NTRA ): Q1 GAAP EPS of -$1.23 misses by $0.07 . Revenue of $241.8M (+24.6% Y/Y) beats by $14.37M . Raising 2023 annual revenue guidance from $990 million to $1.0 billion to a new range of $995 million to $1....

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 m...

2023-05-08 17:35:56 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Occidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Virgin Galactic Holdings ( SPCE ) Upstart Holdings ( UPST ) For further details see: ...

Study with 283 patients, >1,000 plasma samples, and longest follow-up exceeding 5 years demonstrates how ctDNA monitoring can help inform treatment decisions in HR+/HER2- and TNBC patients Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET)...

Includes long-term follow-up data (>5 years) in patients with muscle-invasive bladder cancer and additional studies in colorectal, gastroesophageal and hepatocellular carcinoma Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its ...

Real-world findings from >550 plasma samples highlight prognostic and predictive value of Signatera for adjuvant decision-making and immunotherapy monitoring Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer ...

2023-03-15 11:31:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent rel...

2023-03-08 14:14:51 ET The following slide deck was published by Natera, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Natera, Inc. 2022 Q4 - Results - Earnings Call Presentation